Whalesbook
So, hua kya hai ki US mein jo SelectUSA Summit hua na, wahan Indian companies ne milkar $20.5 billion ka investment karne ka promise kiya hai. Ye aaj tak ka sabse bada figure hai! Ismein sabse zyada hissa pharma companies ka hai, especially Sun Pharma ne ek US ki company Organon & Co. ko $11.75 billion mein khareed liya hai. Is deal se Sun Pharma duniya ki top 25 pharma companies mein aa jayegi, aur uska revenue $12.4 billion tak pahunchne ka target hai. Yeh deal agar regulatory approvals mil gaye toh early 2027 tak final ho jayegi.
Pharma Sector Ka Toofani Raaj!
Pharma sector se hi lagbhag $19.1 billion ka commitment aaya hai. Sun Pharma ki ye deal, jo women's health aur biosimilars mein leader hai, unka global presence badhane mein help karegi. Isse unhe US generics market mein chal rahi price drops aur tough competition se bhi nipatne mein help milegi. CRISIL aur ICRA jaise rating agencies Sun Pharma ki 'AAA' rating ko review kar rahe hain, kyunki ye acquisition kaafi bada hai aur isse debt bhi badh sakta hai.
Sirf Sun Pharma hi nahi, Zydus Lifesciences bhi Assertio Holdings ko $166.4 million mein khareed kar specialty aur oncology business badha raha hai. Aur Jubilant Pharmova bhi FY28 tak $300 million invest karne wala hai US mein sterile injectables ka capacity double karne ke liye.
Baaki Sectors Ka Kya Scene Hai?
Pharma ke alawa bhi kuch companies invest kar rahi hain, lekin unki story thodi alag hai. JSW Steel Ohio aur Texas mein modernization ke liye $255 million laga raha hai, par material costs badh rahi hain, competition bhi hai, aur ek antitrust investigation bhi chal rahi hai.
Sterlite Technologies (STL) data centers ke liye advanced optical fiber supply karne ka plan kar raha hai AI demand ko meet karne ke liye. Stock toh unka badha hai high-bandwidth needs ke karan, par valuation kaafi high hai, debt bhi bahut hai, aur interest coverage weak hai. Unka growth bade tech companies ke spending par depend karta hai.
Clean energy manufacturing mein bhi investment ho raha hai, US policies jaise CHIPS Act aur Inflation Reduction Act se support mil raha hai. Par isme bhi challenges hain. Global clean energy manufacturing mein China kaafi aage hai, aur US ko bhi manufacturing ke liye foreign investment chahiye, jismein policy shifts ka impact padta hai.
Trade Deals Aur Global Risks
Ye bade investments aise time par ho rahe hain jab India-US trade relation badal rahe hain. August 2025 mein US ne Indian goods par 50% tak tariffs lagaye the, jisse trade kam ho gaya tha. Lekin ab February 7, 2026 se ek naye agreement ke baad, US tariffs Indian products par 18% tak aa gaye hain. Isse India ki export competitiveness wapas aayegi, especially textiles, pharma, aur chemicals mein. Par kuch competitors ko abhi bhi US trade preferences ka fayda mil raha hai.
US ki trade policies ka India ke export sectors par pehle bhi impact pada hai aur capital flows par bhi. US ka economic access ko leverage ki tarah use karna India ke export industries ke liye geopolitical risk hai. Haalanki naye trade deal ne tariff structure ko stable kiya hai, fir bhi uncertainties aur global economic volatility ke karan caution toh banta hai.
Investment Risks Kaise Handle Karen?
Itne record investment figures ke bawajood, kai risks hain. STL ka valuation aur financial metrics kamzor hain. JSW Steel rising costs, competition, aur antitrust probe se pressured hai. Sun Pharma ki acquisition se debt badha hai, jisse rating agencies bhi nazar rakh rahi hain. Indian drugmakers ko US pricing pressures aur FDA oversight ka bhi saamna karna padta hai. Semiconductor aur clean energy manufacturing mein growth US govt incentives par depend karta hai, jismein regulatory risks hain. Aur China ka clean tech manufacturing mein strong position bhi ek bada competitive threat hai.
Overall, India se record US investment dikhata hai ki Indian firms global grow karne ki strategy bana rahi hain. Par pharma par itna focus, trade deals ka link, aur alag-alag industries ke challenges ko dekhte hue, future success unke effective integration, global complexities ko manage karne, aur US trade aur industrial policies ko adapt karne par depend karega.